Dulaglutide for the treatment of type 2 diabetes

References

• Polonsky KS. The past 200 years in diabetes. N Engl J Med. 2012;367:1332–1340. ​
   PubMed Web of Science ®Google Scholar
• Banting FG, Best CH, Collip JB, et al. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J. 1922;12:141–146.
   PubMedGoogle Scholar
• Pettus J, Santos Cavaiola T, Tamborlane WV, et al. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016;32:478–496.
   PubMed Web of Science ®Google Scholar
• Johnson IS. Human insulin from recombinant DNA technology. Science. 1983;219:632–637.
   PubMed Web of Science ®Google Scholar
• Hirsch IB. Insulin analogues. N Engl J Med. 2005;352:174–183.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s - Achievements and future developments. Drugs. 1997;54:355–368.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. . Drugs. 1998;55:225–236.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. A review of gliptins for 2014. Exp Opin Pharmacother. 2015;16:43–62.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–442.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary. Endocr Pract. 2016;22:84–113.
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742.
   PubMed Web of Science ®Google Scholar
• Potts JE, Gray LJ, Brady EM, et al. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. Plos One. 2015;10:e0126769.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24:15–30.
   PubMed Web of Science ®Google Scholar
• Barnett AH. Exenatide. Drugs of Today. 2005;41:563–578.
   PubMed Web of Science ®Google Scholar
• Vilsboll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs. 2007;16:231–237.
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Knop FK. Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus. Biodrugs. 2008;22:251–257.
   PubMed Web of Science ®Google Scholar
• Malone J, Trautmann M, Wilhelm K, et al. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2009;18:359–367.
   PubMed Web of Science ®Google Scholar
• Zaccardi F, Htike ZZ, Webb DR, et al. Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis. Ann Intern Med. 2016;164:102–113.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Hessler D, et al. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13:144–149.
   PubMed Web of Science ®Google Scholar
• Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31:1119–1133.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Sanford M. Dulaglutide: first global approval. Drugs. 2014;74:2097–2103.
   PubMed Web of Science ®Google Scholar
• Kuritzky L, Umpierrez G, Ekoe JM, et al. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad Med. 2014;126:60–72.
   PubMed Web of Science ®Google Scholar
• Thompson AM, Trujillo JM. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother. 2015;49:351–359.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dulaglutide (LY-2189265) for the treatment of type 2 diabetes. Expert Rev Clin Pharmacol. 2016;9:385–399.
   PubMed Web of Science ®Google Scholar
• Burness CB, Scott LJ. Dulaglutide: a review in type 2 diabetes. Biodrugs. 2015;29:407–418.
   PubMed Web of Science ®Google Scholar
• Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287–296.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report: Trulicity (dulaglutide). 2014 [ cited published on line;doi; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002825/WC500179473.pdf (latest access February 3, 2017)
   Google Scholar
• Barrington P, Chien JY, Tibaldi F, et al. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab. 2011;13:434–438.
   PubMed Web of Science ®Google Scholar
• Barrington P, Chien JY, Showalter HD, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:426–433.
   PubMed Web of Science ®Google Scholar
• Geiser JS, Heathman MA, Cui X, et al. Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials. Clin Pharmacokinet. 2016;55:625–634.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Trulicity: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002825/WC500179470.pdf ( latest access February 3, 2017)
   Google Scholar
• Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet. 2015;54:1–21.
   PubMed Web of Science ®Google Scholar
• Grunberger G, Chang A, Garcia Soria G, et al. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29:1260–1267.
   PubMed Web of Science ®Google Scholar
• Terauchi Y, Satoi Y, Takeuchi M, et al. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocr J. 2014;61:949–959.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Blevins T, Rosenstock J, et al. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13:418–425.
   PubMed Web of Science ®Google Scholar
• Umpierrez G, Tofe Povedano S, Perez Manghi F, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168–2176.
   PubMed Web of Science ®Google Scholar
• Mari A, Del Prato S, Ludvik B, et al. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic beta-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:834–839.
   PubMed Web of Science ®Google Scholar
• Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37:2149–2158.
   PubMed Web of Science ®Google Scholar
• Loghin C, De La Peña A, Cui X, et al. Gastric emptying effects of dulaglutide in patients with type 2 diabetes mellitus. Abstract presented at the 23rd Annual Scientific & Clinical Congress of the American Association of Clinical Endocrinologists, Las Vegas, May 19, 2014.
   Google Scholar
• Jendle J, Grunberger G, Blevins T, et al. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016;32:776–790.
   PubMed Web of Science ®Google Scholar
• Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349–1357.
   PubMed Web of Science ®Google Scholar
• Dungan KM, Weitgasser R, Perez Manghi F, et al. A 24-week study to evaluate the efficacy and safety of once weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes Metab. 2016;18:475–482.
   PubMed Web of Science ®Google Scholar
• Giorgino F, Benroubi M, Jh S, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38:2241–2249.
   PubMed Web of Science ®Google Scholar
• Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37:2159–2167.
   PubMed Web of Science ®Google Scholar
• Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385:2057–2066.
   PubMed Web of Science ®Google Scholar
• Weinstock RS, Guerci B, Umpierrez G, et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17:849–858.
   PubMed Web of Science ®Google Scholar
• Boustani MA, Pittman I, Yu M, et al. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged >/=65 and <65 years. Diabetes Obes Metab. 2016;18:820–828.
   PubMed Web of Science ®Google Scholar
• Davidson JA, Manghi FP, Yu M, et al. Efficacy and safety of dulaglutide in Hispanic/Latino patients with type 2 diabetes in the AWARD clinical program. Endocr Pract. 2016;22:1406–1414.
   PubMed Web of Science ®Google Scholar
• Grunberger G, Forst T, Fernández Landó L, et al. Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide. Diabet Med. 2016;33:391–394.
   PubMed Web of Science ®Google Scholar
• Wysham C, Guerci B, D’Alessio D, et al. Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:1138–1142.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Stonehouse AH, Han J, et al. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27:309–317.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Pantalone KM, Kwan AY, et al. Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment. Diabetes Obes Metab. 2016;18:615–622.
   PubMed Web of Science ®Google Scholar
• Dungan KM, Raz I, Skrivanek Z, et al. Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme. Diabetes Obes Metab. 2016;18:49–55.
   PubMed Web of Science ®Google Scholar
• Jendle J, Testa MA, Martin S, et al. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy. Diabetes Obes Metab. 2016;18:999–1005.
   PubMed Web of Science ®Google Scholar
• Yu M, Van Brunt K, Varnado OJ, et al. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016;18:419–424.
   PubMed Web of Science ®Google Scholar
• Kim YG, Hahn S, Oh TJ, et al. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:900–909.
   PubMed Web of Science ®Google Scholar
• Miyagawa JI, Odawara M, Takamura T, et al. Once weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomised phase 3 study. Diabetes Obes Metab. 2015;17:974–983.
   PubMed Web of Science ®Google Scholar
• Araki E, Inagaki N, Tanizawa Y, et al. Efficacy and safety of once weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once daily insulin glargine in Japanese patients with type 2 diabetes: a randomised, open-label, phase 3, non-inferiority study. Diabetes Obes Metab. 2015;17:994–1002.
   PubMed Web of Science ®Google Scholar
• Odawara M, Miyagawa J, Iwamoto N, et al. Once weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases HbA1c compared with once daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Diabetes Obes Metab. 2016;18:249–257.
   PubMed Web of Science ®Google Scholar
• Onishi Y, Oura T, Nishiyama H, et al. Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes. Endocr J. 2016;63:263–273.
   PubMed Web of Science ®Google Scholar
• Inagaki N, Araki E, Oura T, et al. The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:1279–1282.
   PubMed Web of Science ®Google Scholar
• Karagiannis T, Liakos A, Bekiari E, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2015;17:1065–1074.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang M, Zhang Y, et al. Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Sci Rep. 2016;6:18904.
   PubMed Web of Science ®Google Scholar
• Fahrbach JL, Fu H, Shurzinske L, et al. Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg. Int J Clin Pract. 2016;70:218–221.
   PubMed Web of Science ®Google Scholar
• Milicevic Z, Anglin G, Harper K, et al. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide. Diabetes Obesity Metab. 2016;18:533–536.
   PubMed Web of Science ®Google Scholar
• Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs–FDA and EMA assessment. N Engl J Med. 2014;370:794–797.
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64:731–737.
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Botros FT, Atisso CM, et al. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2016;15:38.
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health. Researching cardiovascular events with a weekly incretin in diabetes (REWIND). https://clinicaltrials.gov/ct2/show/NCT01394952 ( latest access Feb 03, 2017)
   Google Scholar
• Tuttle KR, Dwight Mckinney T, Davidson JA, et al. The effects of once weekly dulaglutide on kidney function in patients with type 2 diabetes in phase 2 and 3 clinical trials. Diabetes Obes Metab 2016; Oct. 21. doi:10.1111/dom.12816. [Epub ahead of print].
   PubMedGoogle Scholar
• Purnell TS, Joy S, Little E, et al. Patient preferences for noninsulin diabetes medications: a systematic review. Diabetes Care. 2014;37:2055–2062.
   PubMed Web of Science ®Google Scholar
• Gelhorn HL, Poon JL, Davies EW, et al. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naive type 2 diabetes patients in the UK. Patient Prefer Adherence. 2015;9:1611–1622.
   PubMed Web of Science ®Google Scholar
• Gelhorn HL, Bacci ED, Poon JL, et al. Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan. Patient Prefer Adherence. 2016;10:1337–1348.
   PubMed Web of Science ®Google Scholar
• Anderson JE, Thieu VT, Boye KS, et al. Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers. Postgrad Med. 2016;128:810–821.
   PubMed Web of Science ®Google Scholar
• Thompson AM, Trujillo JM. Advances in the treatment of type 2 diabetes: impact of dulaglutide. Diabetes Metab Syndr Obes. 2016;9:125–136.
   PubMed Web of Science ®Google Scholar
• Amblee A. Mode of administration of dulaglutide: implications for treatment adherence. Patient Prefer Adherence. 2016;10:975–982.
   PubMed Web of Science ®Google Scholar
• Matfin G, Van Brunt K, Zimmermann AG, et al. Safe and effective use of the once weekly dulaglutide single-dose pen in injection-naive patients with type 2 diabetes. J Diabetes Sci Technol. 2015;9:1071–1079.
   PubMedGoogle Scholar
• Hauber AB, Nguyen H, Posner J, et al. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Curr Med Res Opin. 2016;32:251–262.
   PubMed Web of Science ®Google Scholar
• Pétré B, Scheen AJ, Ziegler O, et al. Body image discrepancy and subjective norm as mediators and moderators of the relationship between body mass index and quality of life. Patient Prefer Adherence. 2016;10:2261–2270.
   PubMed Web of Science ®Google Scholar
• Noh RM, Graveling AJ, Frier BM. Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review. Expert Opin Pharmacother. 2011;12:2161–2175.
   PubMed Web of Science ®Google Scholar
• Reaney M, Yu M, Lakshmanan M, et al. Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes Obes Metab. 2015;17:896–903.
   PubMed Web of Science ®Google Scholar
• Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6:19–28.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Which incretin-based therapy for type 2 diabetes?. Lancet. 2014;384:1325–1327.
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381:117–124.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289–297.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240–1250.
   PubMed Web of Science ®Google Scholar
• Yabe D, Kuwata H, Usui R, et al. Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points. Curr Med Res Opin. 2015;31:1267–1270.
   PubMed Web of Science ®Google Scholar
• Ross SA. A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes. Curr Med Res Opin. 2015;31:125–135.
   PubMed Web of Science ®Google Scholar
• Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14:77–82.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Nardini C, et al. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomised clinical trials. Diabetes Obes Metabol. 2014;16:38–47.
   PubMed Web of Science ®Google Scholar
• Fisher M, Petrie MC, Ambery PD, et al. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol. 2015;3:697–703.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists. Lancet Diabetes Endocrinol. 2015;3:667–669.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327–336.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Precision medicine: the future in diabetes care?. Diabetes Res Clin Pract. 2016;117:12–21.
   PubMed Web of Science ®Google Scholar